miRecule, Inc., a Gaithersburg MD-based biotech company focused on the development of RNA therapeutics, raised $5.7M in funding.
The round was led by Alexandria Venture Investments, with participation from Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, Additional funding came from the Maryland Momentum Fund and the FSHD Society.
The company intends to use the funds to bring its lead microRNA therapy (MC-30) to clinical development for head & neck cancer.
Led by CEO Anthony Saleh, miRecule leverages the DREAmiR™ discovery platform, which integrates genomic and clinical outcomes data from thousands of patients to identify underlying genetic drivers of disease, and then designs matching RNA therapeutics that directly correct those abnormalities.
The company is applying its platform – developed through over a decade of research in collaboration with the National Institutes of Health in Bethesda, Maryland – to a range of diseases, including cancer, muscular dystrophy, and even viruses such as HIV and COVID-19.